Appendix 4C – Q4 FY23 Quarterly Cash Flow Report

Highlights: ATH434-201 Phase 2 study on track to complete enrollment in Q3 2023 with top-line data expected by the end of 2024 in individuals with...

Related Keywords

New Zealand ,San Francisco ,California ,United States ,United Kingdom ,Australia ,Melbourne ,Victoria ,American ,David Stamler ,Hannah Howlett ,Remy Bernarda ,Alterity Therapeutics ,American Academy Of Neurology Annual Meeting ,Nasdaq ,Securities Exchange ,Alterity Therapeutics Limited ,Data Monitoring Committee ,Multiple System Atrophy ,Monitoring Committee ,History Study ,Therapeutics Limited ,Quarterly Cash Flow Report ,Chief Executive Officer ,Biomarker Study ,American Academy ,Neurology Annual ,Media Contacts ,Securities Act ,Securities Exchange Act ,Australian Stock Exchange Ath Ax ,Clinical Trials ,Rare Disease ,